Our ground-breaking technologies and research results are available for partnering and commercialisation.

The following projects can be accessed through UWA's Research Development and Innovation office:

 

Gadolinium Oxide (Gd2O3): A safe and lightweight X-Ray Shielding Material

UWA-XRay Shielding
UWA-XRayShielding [PDF, 233.9 KB]
Updated 23 Jan 2017


UWA Researchers have developed an environmentally friendly X-Ray shielding material using finely dispersed nano-sized Gadolinium Oxide as an alternative to toxic lead based materials.

Partner with us

 

PUF protein-based RNA binding and modulation technology

Researchers at the University Of Western Australia Perkins Institute Of Medical Research have discovered a universal code for protein-RNA recognition, presenting the possibility of a platform for developing designer-RNA binding protein reagents for the study and manipulation of RNA.

Partner with us

 

Flash flaming of seeds to improve land restoration

UWA researchers have developed a device that carefully heats seeds to remove the fluffy appendages that make many seeds difficult to store, transport, coat and handle.  The device will have an impact in large scale land revegetation projects, such as minesite restoration.

Partner with us

 

Child-friendly pharmaceutical formulation to mask the taste of medicines

UWA researchers have developed a chocolate based, pharmaceutical formula that masks the taste of bitter drugs such as midazolam, thereby ensuring therapeutic compliance with minimal distress in young children.

Partner with us

 

Improved Efficiency MED Evaporation / Liquid Stream Concentration

Using waste heat sources from 65-90oC, this technology improves the efficiency of Multiple Effect Distillation/Evaporation processes, increasing freshwater production by 30 to 55% while simultaneously reducing heat rejection loads to evaporation towers or ponds.

Partner with us

 

Arginine-rich neuroprotective peptides

UWA researchers have discovered intrinsic neuroprotective properties of arginine-rich peptides, presenting the possibility of a new class of neuroprotective molecules for the treatment of a range of neurological disorders, including stroke.

Partner with us

 

Triple negative breast cancer therapy

UWA researchers have developed a compound that selectively decreases chemoresistance in triple negative tumours providing a new therapeutic opportunity for these cancer patients.

Partner with us

 

Interfacial Toughening of composites with ultra-thin Kevlar® layer

The weakest link of adhesive joints, or between layers of composite materials, is typically a thin layer of e.g. epoxy resin.  Adding an ultra-thin layer of aramid fibres to this thin resin layer in question can significantly improve the performance of the joint / composite component. Protruding free fibre ends of the short Kevlar fibres connect/bridge the interface and thus improve adhesion.

Partner with us

 

A platform for identifying new synergistic drug-immunotherapy combinations

A platform for identifying new synergistic drug-immunotherapy combinations

A network analysis approach for identifying novel IO-drug combinations, based on the study of gene expression signatures in immunotherapy-induced progressing or regressing tumours.

Partner with us

 

Novel Zeolite Adsorbents for separation of Methane and Nitrogen

A novel Zeolite-based adsorbent for separation of methane and nitrogen with a selectivity of 6-8 - outperforming all known industrial adsorbents in its ability to separate methane from nitrogen and it is well suited for Swing Adsorption methods (such as Pressure Swing Adsorption and Vacuum Swing Adsorption).

Partner with us

 

Tumour targeted LIGHT (TNFSF14) therapy

Tumour targeted LIGHT (TNFSF14) therapy

UWA researchers have developed a novel targeted-cytokine drug, LIGHT-RGR, which is shown to promote tumour vasculature normalization, and to enhance tumour perfusion and infiltration of activated immune cells. LIGHT-RGR has significant potential in checkpoint immunotherapy-combination approaches, and also as an adjunct to enhance trafficking and infiltration of engineered T cells (CAR-T cell therapies) into solid tumours.

Partner with us

 

High-Performance Dual Reflux Swing Adsorption System

Researchers at UWA have developed a novel design methodology for Dual Reflux Pressure Swing Adsorption (DR-PSA) systems that leads directly to the optimum design for a set of given inputs with excellent correlation between simulation and implementation thus eliminating costly and time consuming trial & error.

Partner with us

 

A novel matrix-targeted anti-cancer drug

A novel matrix-targeted anti-cancer drug

UWA researchers have developed a novel targeted-TNF anti-cancer therapy which causes highly selective degradation of tumour-extra cellular matrix (ECM). In models of liver, breast and pancreatic cancer this drug is shown to reduce ECM content, tumour stiffness and interstitial pressure, and to increase tumour perfusion.

This targeted-TNF also has anti-tumorigenic monotherapeutic effects, however unlike native TNF, this drug does not cause systemic toxicity.

Partner with us

 

High-Intensity Magnetic Field Focusing Cavity

Researchers at UWA have developed a Multi-post 3D Split Ring Re-entrant Cavity Lattice as a hybrid platform for integration of quantum systems – suitable for multi-frequency sensing, probing of magnetic and dielectric properties of solids (spectroscopy) and many other "quantum" applications.

Partner with us

 

Methods for beta cell maturation towards a diabetes cell therapy

Methods for beta cell maturation towards a diabetes cell therapy

UWA researchers have developed protocols and reagents for the generation of fully functionalized insulin-secreting beta cells for potential use in the treatment of insulin-dependent diabetes. Specifically it is shown that islet progenitor cells, derived from stem cell lineages, may be differentiated into a fully mature beta cells, with immediate and sustained potency.

Partner with us